Shots:
Upstream Bio presented results from the P-II VALIANT study evaluating verekitug in 478 adults with severe asthma, with the study meeting its 1EP of reducing the annualized asthma exacerbation rate (AAER) across all dose regimens.
Verekitug 100 mg dosed every 12 wks. reduced AAER by 56% vs. PBO (p<0.001) and also improved lung function…
